KLF4 and cancer: [23], [24], [25]. Recent studies indicate that miRNAs regulate EMT or MET pathways by targeting epithelial or mesenchymal cell marker genes that include miR-194, miR-203, and miR-200c [22], [26]. KLF4 has been shown to regulate EMT in several different cancer cells. In hepatocellular carcinoma, breast, and prostate cancer cells, KLF4 activates the transcription of the epithelial cell marker gene E-cadherin and represses the mesenchymal cell marker gene snail 2(slug) by binding to their respective promoters. KLF4 in these cancers promotes MET and inhibits tumor cell growth [10], [24], [27].